Adaptive Biotechnologies Corp

Our company advances immune medicine by using proprietary technologies to decode a patient's adaptive immune system. This involves reading the genetic code of the immune system to understand how it detects and treats disease. These insights are stored in a clinical immunomics database, supported by computational biology and machine learning, to develop and commercialize tailored clinical products and services. In 2024, the company reorganized into two main businesses: the "MRD business" and "Immune Medicine" (IM business). The MRD business focuses on the clinical assessment of minimal residual disease (MRD) in lymphoid malignancies. This business utilizes a highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It includes the clonoSEQ clinical diagnostic test for clinicians and the clonoSEQ assay for biopharmaceutical partners to support drug development ("MRD Pharma"). The total addressable market for the MRD business is approximately $6.2 billion, with approximately $5.3 billion from clinical testing. clonoSEQ is the first FDA-authorized test for detecting and monitoring MRD in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). It is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, including diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The IM business focuses on creating applications and products that connect adaptive immune responses to disease.